알코올 사용 장애의 약물치료 = Pharmacotherapy of Alcohol Use Disorders

다국어 초록 (Multilingual Abstract)

Alcoholism, a major public health problem throughout the world, causes enormous damage to health and quality of life and undermines the well-being of families and society, It is associated with liver disease, cancer, cardiovascular problems, acci-dental deaths, suicides, and homicides.
Over the last 20 years, rational drug treatment have arisen from better understanding of the neurobiological substrates of alcohol dependence, including adaptive changes in amino acid neurotransmitter systems, stimulation of dopamine and opioid peptide systems, and, possibly, changes in serotonergic activity. Disulfiram, naltrexone and acamprosate are currently the only treatments approved for the management of alcohol dependence. Data from studies of ondansetron and topiramate in alcohol dependence are somewhat promising, but it appears that these drugs have not yet demonstrated evidence of efficacy in large controlled clinical trials. Trials with SSRIs and some antipsychotics have yielded disappointing results.
Because the biological basis of alcohol dependence appears to be multifactorial, the future of management of alcoholism may be combination therapy, using drugs acting on different neuronal pathways, such as acamprosate and naltrexone. Phannacothe-rapy should be used in association with appropriate psychosocial support and specific treatment provided for any underlying psychiatric comorbidities.

참고문헌 (Reference)

1 "VeteransAffairs Naltrexone Cooperative Study 425 Group:naltrexone in thetreatment of alcohol dependence" 345 : 1734-1739, 2001

2 "United Kingdom multicentreacamprosate study(UKMAS)a 6 month prospective study ofacamprosate vs placebo in preventing relapse after withdrawal fromalcohol" 35 : 176-18, 2000

3 "Tiapride in the prevention of relapse in recently detoxified alcoholics" 165 : 515-523, 1994

4 "The effects of clozapine onalcohol and drug use disorders among patients with schizophrenia" 26 : 441-449, 2000

5 "Six-month follow-up of naltrexone and psychotherapyfor alcohol dependence" 53 : 271-224, 1996

6 "Sertraline treatment for alcohol dependence:interactive effectsof medication and alcoholic subtype" 24 : 1041-1049, 2000

7 "Relapse preventionby acamprosate:Results from a placebo-controlled study on alcoholdependence" 53 : 673-680, 1996

8 "Psychotherapeutic considerations in pharmacologicaltrials" 20 : 17A-22A, 1996

9 "Pharmacologicaltreatment of alcohol dependence: a review of the evidence" 281 : 1318-1325, 1999

10 "Pharmacodynamics and pharmacokineticsof acamprosate: An overview" 47-64, 1995

11 "Oral topiramate for treatment of alcohol dependence:a randomised controlled trial" 361 : 1677-1685, 2003

12 "Ondansetron for reduction of drinking among biologicallypredisposed alcoholic patients:a randomized controlled trial" 284 : 963-971, 2000

13 "Naltrexone:disposition,metabolism,and effect after acute and chronic dosing" 20 : 315-328, 1976

14 "Naltrexone in the treatmentof alcohol dependence" 49 : 876-880, 1992

15 "Naltrexone and coping skill therapy for alcohol dependence:A controlled study" 49 : 881-887, 1992

16 "Measurementof compliance with naltrexone in the treatment of alcohol dependence:research and clinical implications" 60 : 449-453, 1999

17 "Lone-acting injectable bromocriptinedose not reduce relapse in alcoholics" 92 : 969-978, 1997

18 "Initial and Maintenance Naltrexone Treatment forAlcohol Dependence Using Primary Care vs Specialty Care:A NestedSequence of 3 Randomized Trials" 163 : 1695-1704, 2003

19 "Fluoxetine treatmentseems to reduce the beneficial effects of cognitive-behavioral therapyin type B alcoholics" 20 : 1534-1541, 1996

20 "Fluoxetine in depressed alcoholics:a double-blind,placebocontrolledtrial" 54 : 700-705, 1997

21 "Experience of a "slip"among alcoholics treated with naltrexone or placebo" 153 : 281-283, 1996

22 "Efficacyand safety of acamprosate in the treatment of detoxified alcohol-dependentpatients:A 90-day placebo-controlled dose-finding study" 171 : 73-75, 1997

23 "Efficacy offluvoxamine in preventing relapse in alcohol dependence:a one-year,double-blind,placebo-controlled multicentre study with analysis bytypology" 74 : 61-70, 2004

24 "Effects of citalopram and abrief psycho-social intervention on alcohol intake,dependence andproblems" 90 : 87-99, 1995

25 "Effect of naltrexone on human alcohol consumption" 56 : 24-29, 1995

26 "Doubleblindrandomized multicentre trial of acamprosate in maintainingabstinence from alcohol" 30 : 239-247, 1995

27 "Does disulfiram have a role in alcoholism treatmenttoday?" 99 : 21-24, 2004

28 "Disulfiram treatment of alcoholism:a veterans administrationcooperative study" 256 : 1449-1455, 1986

29 "Development of novel pharmacotherapies for the treatmentof alcohol dependence:focus on antiepileptics" 28 : 295-301, 2004

30 "Buspirone treatment of anxious alcoholics:a placebo-controlledtrial" 51 : 720-731, 1994

31 "Buspirone treatment of alcoholism: age of onset, and cerebrospinalfluid 5-hydroxyindolacetic acid and homovanillic acid concentrations,but not medication treatment, predict return to drinking" 23 (23): 272-278, 1999

32 "Buspirone in the treatment of alcoholic patients" 22 : 49-59, 1985

33 "Bioequivalence,dose-proportionality and pharmacokinetics of naltrexone" 45 : 15-19, 1984

34 "Alcohol abuse and alcoholism:an overview" 62 : 4-10, 2001

35 "Acamprosate in alcohol dependence how does it work?" 90 : 1179-1188, 1995

36 "Acamprosate in Korean alcohol dependentpatients: a multi-center, randomized, double-blind, placebo-controlledstudy" 38 : 135-141, 2003

37 "Acamprosate and naltrexone treatment for alcohol dependence:Van evidence-based risk-benefits assessment" 13 : 469-475, 2003

38 "A preliminary report onpossible naltrexone and nonsteroidal analgesic interactions" 21 : 632-634, 2001

39 "A multicenter safety study ofnaltrexone as adjunctive pharmacotherapy for individuals with alcoholism" 20-25, 1995

40 "A double-blind,placebo-controlled study of olanzapine in thetreatment of alcohol-dependence disorder" 28 : 736-745, 2004